PLASMA KALLIKREIN INHIBITORS

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary ang...

Full description

Saved in:
Bibliographic Details
Main Authors CERNAKA, Natalija, JABRI, Salman, TIAN, Maoqun, OGAWA, Anthony Ken, GAO, Ying-Duo, SHARP, Phillip Patrick, BAO, Jianming, TANG, Haiqun, LOPEZ, Jovan Alexander, XIAO, Dong, YANG, Song, SINZ, Christopher, CHENG, Alan, OSLER, Skylar, MERCHANT, Rohan
Format Patent
LanguageEnglish
French
Published 27.05.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein. La présente invention concerne des composés de formule (I) et des compositions pharmaceutiques comprenant un ou plusieurs desdits composés, et des procédés d'utilisation desdits composés pour traiter ou prévenir un ou plusieurs états pathologiques qui pourraient bénéficier de l'inhibition de la kallicréine plasmatique, y compris l'angioedème héréditaire, l'uvéite, l'uvéite postérieure, l'oedème maculaire lié à l'âge humide, l'oedème maculaire diabétique, la rétinopathie diabétique et l'occlusion de la veine rétinienne. Les composés sont des inhibiteurs sélectifs de la kallicréine plasmatique.
Bibliography:Application Number: WO2021US59930